Broad Institute

JUNE 21, 2023

Now, researchers at the Broad Institute of MIT and Harvard have found that treatment with continuous hypoxia — low-oxygen conditions comparable to levels at a Mount Everest base camp — restores balance and coordination in a mouse model of Friedreich’s ataxia. A few treatments stood out.

Treatment 98

Treatment Disease Molecular Biology Medical Schools 98

Drug Target Review

NOVEMBER 27, 2023

In cancer, the eIF4F complex becomes dysregulated, leading to the excessive production of these proteins, which contribute to tumour formation and resistance to treatment. STRIs represent a fundamentally different approach to cancer therapy compared to traditional treatments like chemotherapy, radiation therapy, and targeted therapies.

Molecular Biology 86

Molecular Biology Therapies Pharmaceuticals Treatment 86

Drug Target Review

NOVEMBER 8, 2023

Cell therapies hold immense promise for revolutionising the treatment of some of the most challenging diseases, but several technological and logistical hurdles stand in the way of unlocking their full potential. These patients typically fail frontline chemotherapies within 8 months of treatment and have few options for second line therapies.

Therapies 116

Therapies Engineering Treatment Molecular Biology 116

LifeSciVC

AUGUST 5, 2024

The proteosome inhibitor, approved for treatment of multiple myeloma and mantle cell lymphoma, has been an important medicine for patients but it isn’t a product of the genomics revolution. In fact, the Millennium of 2001 (pre-Takeda acquisition) had one drug approved which was Velcade (bortezomib). One final parallel to 2001.

Molecular Biology 88

Molecular Biology Production Drug Development Small Molecule 88

Drug Target Review

JULY 1, 2024

As a non-opioid, SRP-001 also eliminates abuse potential, positioning it as a safer and effective drug candidate for the treatment of acute and neuropathic pain and migraine headache. How does SRP-001’s safety profile, especially concerning hepatotoxicity and nephrotoxicity, compare to other common pain medications?

Treatment 59

Treatment Clinical Trials Therapies Molecular Biology 59

Drug Target Review

APRIL 19, 2024

Sibylla’s scientific founders come from very different scientific fields that do not usually speak to each other, such as theoretical physics, molecular biology and pharmaceutical chemistry. And so, I have been the managerial co-founder and CEO of Sibylla since 2017. This multidisciplinary approach is at the heart of Sibylla.

Molecular Biology 111

Molecular Biology Research Pharmaceuticals Small Molecule 111

Drug Target Review

SEPTEMBER 22, 2023

8 Furthermore, the absence of immune, mesenchymal, or endothelial cells limits the applicability of organoids for the assessment of certain therapies, such as immuno-oncology treatments or drug metabolism studies where more complex models are needed. Nat Rev Bioeng [Internet]. 2023 Jan 19;1(1):32–45. 95: 729–38

Clinical Research 116

Clinical Research Research Drug Development Molecular Biology 116

The Pharma Data

FEBRUARY 25, 2022

. “The SARS-CoV-2 vaccines target the spike protein, but this protein is under strong selection pressure and, as we have seen with Omicron, can undergo significant mutations,” said Joyce Jose, assistant professor of biochemistry and molecular biology, Penn State. 25) in the journal Communications Biology.

FDA Approval 52

FDA Approval FDA Molecular Biology Virus 52

Broad Institute

JANUARY 30, 2024

In others, an infection can cause the immune system to spin out of control, leading to sepsis — organ dysfunction that lacks effective treatments and is often fatal. In 2005, Bhattacharyya completed PhD studies at the University of California, San Francisco, in biochemistry and molecular biology, followed by two years of medical training.

Hospitals 137

Hospitals Virus Medical Schools Science 137

Drug Target Review

JUNE 19, 2024

Our goal is to stand on the shoulders of giants and advance this exciting and new field of medicine, so that it can deliver valuable treatments to patients. How do you envision the future of cell therapy and its potential impact on medical treatments and healthcare? Could you give us an overview of the Lineage platform?

Therapies 84

Therapies Small Molecule Pharmaceutical Companies Molecular Biology 84

Drug Target Review

FEBRUARY 28, 2024

Over the past 25 years, T-cell therapies have gained significant ground in the treatment of cancer. Dr Rochlin earned a PhD in Molecular Biology and Genetics from Weill Cornell Medical College, conducting research at Sloan Kettering Institute, and a BA in Biology from the University of Pennsylvania. Fisher J, Anderson.

Therapies 105

Therapies Engineering Molecular Biology Science 105

Drug Target Review

MAY 27, 2024

What role do ADCs play in Caris’ strategy for targeted cancer therapy, particularly in terms of patient-specific treatment plans? At a base-layer, Caris’ comprehensive molecular profiling that we perform for patients today can identify predictive biomarkers for current FDA-approved ADCs. Examples include HER2-low and FOLR1.

Clinical Trials 59

Clinical Trials Science Molecular Biology Bioinformatics 59

The Pharma Data

NOVEMBER 10, 2021

Treatment is delicate and limited, making it decreasingly critical to find new curatives. ” Numerous cancer cases respond well to primary treatment, which frequently gives cases and croakers an original sense of excitement or stopgap. The overall prognostic for survival is grim, with a five- time relative survival rate of just18.4

Disease 52

Disease Molecular Biology RNA Drugs 52

The Pharma Data

NOVEMBER 23, 2020

Legend was launched to expand GenScript’s capabilities of developing a broad range of immunotherapy treatments. Food and Drug Administration last year and appears to be on track for a potential regulatory review as a treatment for multiple myeloma next year. as a director of molecular biology.

Government 52

Government Molecular Biology Regulations Laboratories 52

The Pharma Data

APRIL 28, 2021

In the past two decades we have learned so much in oncology about the molecular biology of cancer and that has led to better treatments for patients. These digital analyses could indicate disease or mechanistic activity in patients or be associated with treatment response,” Gallagher said. Source link.

Molecular Biology 40

Molecular Biology Doctors Disease Treatment 40

Drug Target Review

AUGUST 29, 2023

The implication of this work is that we have an unprecedented opportunity to advance a single tRNA medicine to unify treatment across a wide range of diseases with the same underlying genetic mutation, enabling us to provide medicines to patients, especially those with rare or ultra-rare diseases, with no or limited treatment options.

Science 98

Science Disease Molecular Biology Therapies 98

Broad Institute

AUGUST 7, 2023

One potential reason that other STING agonists have not made it beyond clinical trials is that the treatment can result in unwanted cell death mediated by STING. Food and Drug Administration has not approved any STING agonist thus far, although multiple clinical trials are currently underway. Paper Cited Liu B, Carlson R, et al.

Regulations 91

Regulations Clinical Trials Engineering Science 91

Drug Target Review

FEBRUARY 26, 2024

Rather than solely identifying tumour-associated mutations which can be specifically targeted for effective treatment, we now need to consider how non-mutational events play into both the development of the primary tumour and the development of therapy resistance.

Therapies 59

Therapies Molecular Biology Regulations Medical Schools 59

Codon

FEBRUARY 13, 2024

doi: 10.2210/rcsb_pdb/goodsell-gallery-048 The Virus that Cures It’s been over 25 years since the science magazine Discover first ran an extraordinary article about how a long-forgotten medical treatment, used in the former Soviet country of Georgia, could save us from the growing threat of untreatable, drug-resistant infections.

Therapies 124

Therapies Virus DNA Clinical Trials 124

The Pharma Data

MARCH 25, 2022

The findings, which are described in the journals Nature Communications and Science Advances, could pave the way for new treatments against COVID-19. This part of the study was conducted in collaboration with Hrishikesh Das and Martin Hällberg at the Department of Cell and Molecular Biology at Karolinska Institutet.

Molecular Biology 52

Molecular Biology Laboratories Cell Biology Science 52

Alta Sciences

MARCH 1, 2024

It wasn’t until 1990 that the first successful gene therapy treatment on a patient transpired. Q: What are some advancements in gene therapy treatments that you are hoping to explore further? PJ: One of the newest and most promising treatments I am looking to explore is for blood cancer.

Therapies 52

Therapies Laboratories Molecular Biology RNA 52

The Pharma Data

FEBRUARY 22, 2021

Born in 1970, the British and American research scientist has been Director of the Department of Microbiome Research at the Max Planck Institute for Developmental Biology in Tübingen since 2016. Before, she was associate professor at Cornell University in the Department of Molecular Biology and Genetics.

Molecular Biology 40

Molecular Biology Science Vaccine Laboratories 40

The Pharma Data

JANUARY 6, 2021

Ichtchenko’s hypothesis that the C1 ad delivery vehicle previously reported could be used to transport therapeutic proteins into the neuronal cytosol, researchers led by Dr. Ichtchenko developed and tested a potential treatment for botulism based on intracellular inhibition of the BoNT subtype A1 light chain metalloprotease (LC/A1).

Science 52

Science Molecular Biology Treatment Production 52

Drug Target Review

OCTOBER 25, 2024

How does precision neuroscience differ from traditional approaches in the treatment of neurodegenerative diseases, and what advantages does it offer? What role do large biofluids proteomics datasets play in characterising the molecular processes that drive disease progression? Progress in molecular biology and translational science.

Disease 59

Disease Clinical Trials Therapies Science 59

The Pharma Data

JANUARY 18, 2021

Fox Foundation continues to fund our cutting-edge science in their mission to transform the way new Parkinson’s disease treatments are developed and tested,” says Dr. Charlotte D’Hulst, CEO & Co-Founder of Yesse Technologies, Inc. “We are thrilled that The Michael J.

Disease 40

Disease Molecular Biology Licensing Licensing 40

The Pharma Data

NOVEMBER 18, 2021

The company has completed proof-of- conception studies by developing first- by- class impediments targeting preliminarily undruggable TFs for the treatment of idiopathic pulmonary fibrosis (IPF), Ewing’s Sarcoma, prostate cancer and facioscapulohumeral muscular dystrophy (FSHD).

Molecular Biology 52

Molecular Biology Pharmaceuticals Laboratories Clinical Development 52

The Pharma Data

NOVEMBER 19, 2020

Structure-based design approach has identified potent compounds for further development as oral treatments for SARS-CoV-2 infection and related human coronaviruses. Program focused on inhibitors of SARS-CoV-2 main protease, a highly conserved protein essential for viral replication. References.

Small Molecule 40

Small Molecule Structure Based Drug Design (SBDD) Molecular Biology International 40

Drug Target Review

APRIL 8, 2024

How might the integration of AI predictions into clinical practice impact the treatment approach for patients with early-stage NSCLC? Dr Cote : The decision to treat an early-stage NSCLC with systemic therapy (chemotherapy, immune therapy) is not easy, as many patients will be cured without such treatment. Coulter Jr.

Hospitals 52

Hospitals Therapies Clinical Trials Molecular Biology 52

The Pharma Data

SEPTEMBER 15, 2020

Our Trilomer® platform of peptidomimetic binders allows for the targeted inhibition of disease-causing proteins, for the treatment of cancer, autoimmune diseases, infectious diseases, and others. Each site has a complete molecular biology core facility that allows companies to do experiments on day one, not year one.

Targeted Protein Degradation 52

Targeted Protein Degradation Molecular Biology Small Molecule Science 52

The Pharma Data

SEPTEMBER 17, 2020

6 This is being explored as an adjunctive treatment for the management of COVID-19.6 Roche remains committed to continuing the Actemra/RoActemra clinical trial programme in COVID-19 to further explore Actemra/RoActemra in other treatment settings, including in combination with an antiviral. The molecular biology of coronaviruses.

Vaccine 52

Vaccine Virus Clinical Trials Immune Response 52

Codon

DECEMBER 17, 2023

Molecular biology, as the field came to be called 3 , pushed biology from an object of study, driven forward by gentleman scientists and precocious country clergymen, into a tool with which to solve urgent problems. Natural History museums sprung up to display biological oddities; nearly 800 of them in the United States alone.

Engineering 52

Engineering Molecular Biology Doctors DNA 52

The Pharma Data

JANUARY 25, 2021

With a background in molecular biology and clinical chemistry, Dr. Zetterberg has spent the last 20 years focusing on the development of biomarkers for Alzheimer’s disease, Parkinson’s disease and other brain disorders. . – January 26, 2021) – NervGen Pharma Corp. About NervGen.

Disease 40

Disease Clinical Development Molecular Biology Treatment 40

The Pharma Data

JANUARY 21, 2021

Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to eight FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories.

Science 40

Science Engineering Molecular Biology Bioinformatics 40

Codon

JUNE 18, 2024

Even after a half-century of molecular biology research, scientists didn’t know until recently how gas vesicles physically trap gas while occluding water. angstroms, or roughly twice the length of a single carbon-carbon bond. .

Engineering 67

Engineering Laboratories International Clinical Trials 67

Codon

MARCH 12, 2023

I recently asked for recommendations of “classic” papers in molecular biology. A phase 3 study of an AAV5-based therapy for hemophilia B (which causes uncontrolled bleeding) reduced bleeding events by 64 percent; the 54 treated men were monitored between 7 and 18 months post-treatment.

DNA 52

DNA Engineering Therapies RNA 52

Agency IQ

JANUARY 19, 2024

To start, a tissue sample is harvested and the cells of interest are isolated using method(s) such as enzymatic digestion, chemical treatment, or mechanical dissociation. Among these are considerations for highly pure and concentrated virus stocks for spiking and notes for when molecular biology assays are used to quantify viral genomes.

Virus 40

Virus Science Production FDA 40

Drug Target Review

FEBRUARY 15, 2024

Advances in molecular biology have led to highly safe, efficient, and effective platforms, such as mRNA, that can be rapidly re-purposed for different pathogens, multiple pathogens, or new strains of evolving pathogens. Oral Tecovirimat for the Treatment of Smallpox. Vaccines, however, do have some critical limitations.

Drug Development 122

Drug Development Virus Vaccine Government 122